Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 3 | 1 |
| List of Figures | 4 | 1 |
| Report Guidance | 5 | 1 |
| Clinical Trials by Region | 6 | 8 |
| Clinical Trials and Average Enrollment by Country | 7 | 2 |
| Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 9 | 1 |
| Top Five Countries Contributing to Clinical Trials in Europe | 10 | 1 |
| Top Countries Contributing to Clinical Trials in North America | 11 | 1 |
| Top Countries Contributing to Clinical Trials in Middle East and Africa | 12 | 1 |
| Top Countries Contributing to Clinical Trials in Central and South America | 13 | 1 |
| Clinical Trials by G7 Countries: Proportion of Vulvovaginal Candidiasis to Infectious Disease Clinical Trials | 14 | 1 |
| Clinical Trials by Phase in G7 Countries | 15 | 1 |
| Clinical Trials in G7 Countries by Trial Status | 16 | 1 |
| Clinical Trials by E7 Countries: Proportion of Vulvovaginal Candidiasis to Infectious Disease Clinical Trials | 17 | 1 |
| Clinical Trials by Phase in E7 Countries | 18 | 1 |
| Clinical Trials in E7 Countries by Trial Status | 19 | 1 |
| Clinical Trials by Phase | 20 | 2 |
| In Progress Trials by Phase | 21 | 1 |
| Clinical Trials by Trial Status | 22 | 1 |
| Clinical Trials by End Point Status | 23 | 1 |
| Subjects Recruited Over a Period of Time | 24 | 1 |
| Clinical Trials by Sponsor Type | 25 | 1 |
| Prominent Sponsors | 26 | 3 |
| Top Companies Participating in Vulvovaginal Candidiasis Therapeutics Clinical Trials | 27 | 2 |
| Prominent Drugs | 29 | 1 |
| Latest Clinical Trials News on Vulvovaginal Candidiasis | 30 | 5 |
| Aug 15, 2016: NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal Immunotherapy in a Phase 2a Study in Women with Recurrent Vulvovaginal Candidiasis | 30 | 1 |
| Aug 10, 2016: Positive Interim Clinical Results for VT-1161 to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting | 31 | 1 |
| Aug 09, 2016: Cidara Therapeutics Announced Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting | 31 | 1 |
| Jun 09, 2016: Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis | 32 | 1 |
| Jun 08, 2016: SCYNEXIS Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors | 32 | 1 |
| Jun 08, 2016: Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016 | 33 | 2 |
| Clinical Trial Profile Snapshots | 35 | 50 |
| Appendix | 85 | 3 |
| Abbreviations | 85 | 1 |
| Definitions | 85 | 1 |
| Research Methodology | 86 | 1 |
| Secondary Research | 86 | 1 |
| About GlobalData | 87 | 1 |
| Contact Us | 87 | 1 |
| Disclaimer | 87 | 1 |
| Source | 88 | 1 |